HomeCompareDCCPY vs PFE

DCCPY vs PFE: Dividend Comparison 2026

DCCPY yields 5.03% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DCCPY wins by $226.8K in total portfolio value
10 years
DCCPY
DCCPY
● Live price
5.03%
Share price
$29.68
Annual div
$1.49
5Y div CAGR
41.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$276.3K
Annual income
$126,626.42
Full DCCPY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DCCPY vs PFE

📍 DCCPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCCPYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCCPY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCCPY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCCPY
Annual income on $10K today (after 15% tax)
$427.31/yr
After 10yr DRIP, annual income (after tax)
$107,632.46/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, DCCPY beats the other by $85,312.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCCPY + PFE for your $10,000?

DCCPY: 50%PFE: 50%
100% PFE50/50100% DCCPY
Portfolio after 10yr
$162.9K
Annual income
$76,442.57/yr
Blended yield
46.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DCCPY
No analyst data
Altman Z
5.7
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCCPY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCCPYPFE
Forward yield5.03%6.13%
Annual dividend / share$1.49$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR41.9%13.2%
Portfolio after 10y$276.3K$49.6K
Annual income after 10y$126,626.42$26,258.71
Total dividends collected$238.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DCCPY vs PFE ($10,000, DRIP)

YearDCCPY PortfolioDCCPY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,413$713.36$9,153$693.39+$2.3KDCCPY
2$13,292$1,079.75$8,593$849.25+$4.7KDCCPY
3$15,890$1,667.63$8,336$1,066.78+$7.6KDCCPY
4$19,646$2,643.83$8,437$1,384.80+$11.2KDCCPY
5$25,356$4,334.96$9,013$1,875.40+$16.3KDCCPY
6$34,551$7,419.80$10,306$2,680.72+$24.2KDCCPY
7$50,378$13,408.05$12,820$4,101.38+$37.6KDCCPY
8$79,831$25,926.30$17,673$6,826.70+$62.2KDCCPY
9$139,903$54,483.99$27,543$12,591.86+$112.4KDCCPY
10$276,322$126,626.42$49,560$26,258.71+$226.8KDCCPY

DCCPY vs PFE: Complete Analysis 2026

DCCPYStock

DCC plc provides sales, marketing, and support services worldwide. The company's DCC LPG segment sells and markets liquefied petroleum gas (LPG), refrigerants, and natural gas. Its DCC Retail & Oil segment markets, sells, and retails transport and commercial fuels, heating oils, and related products and services; operates retail petrol stations; resells fuel cards; distributes oil; and provides inbound logistics, storage and filling, and outbound logistics services. This segment serves domestic, agricultural, commercial/industrial, forecourt, aviation, and marine customers. The company's DCC Healthcare segment offers products and services to healthcare providers, and health and beauty brand owners; outsourced contract manufacturing services to the health and beauty sector; nutrition products, such as vitamins and health supplements; beauty products; and product development, formulation, manufacturing, and packaging services. In addition, this segment procures and sells exempt medicinal products. Its DCC Technology segment distributes consumer technology products, including smart home products, gaming consoles, peripherals and software, wearable technology, and accessories; business and enterprise technology products, such as tablets, notebooks, and PCs; networking and security products; communication products comprising smartphones; and servers and storage products, audio visual products, printers, peripherals, cables and connectors, and consumables to retailers, resellers, and integrators. It also provides supply chain services. The company was founded in 1976 and is headquartered in Dublin, Ireland.

Full DCCPY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DCCPY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCCPY vs SCHDDCCPY vs JEPIDCCPY vs ODCCPY vs KODCCPY vs MAINDCCPY vs JNJDCCPY vs MRKDCCPY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.